Hepatocellular Carcinoma. Part 3: Surgical and Medical Treatment
Hepatocellular carcinoma (HCC) treatment is variable and depends on the size, location, and presence of extra hepatic metastasis and vascular invasion. HCC treatment options have advanced significantly over the past few decades and include surgical and non-surgical methods. In the past, systemic che...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
European Medical Journal
2018-06-01
|
Series: | European Medical Journal Hepatology |
Subjects: | |
Online Access: | https://www.emjreviews.com/hepatology/article/hepatocellular-carcinoma-part-3-surgical-and-medical-treatment/ |
id |
doaj-3c0626c51dd3463380f184bb04b16940 |
---|---|
record_format |
Article |
spelling |
doaj-3c0626c51dd3463380f184bb04b169402020-11-24T23:20:35ZengEuropean Medical JournalEuropean Medical Journal Hepatology2053-42212018-06-01518996Hepatocellular Carcinoma. Part 3: Surgical and Medical TreatmentLior Charach0Lior Zusmanovitch1Gideon Charach2Department of Internal Medicine C Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelDepartment of Internal Medicine C Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelDepartment of Internal Medicine C Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelHepatocellular carcinoma (HCC) treatment is variable and depends on the size, location, and presence of extra hepatic metastasis and vascular invasion. HCC treatment options have advanced significantly over the past few decades and include surgical and non-surgical methods. In the past, systemic chemotherapy was the non-surgical treatment and there was no significant increase in overall survival rate. Nowadays sorafenib, a molecular targeted drug, is the treatment of choice and has shown proven benefits in increasing survival time; other systemic therapies did not show longer statistical superiority. However, surgical treatments, such as liver transplantation and surgical resection, are still the only methods offering a curative opportunity; however, these are not free of adverse effects and recurrence of the tumour. Non-surgical techniques including ablative treatment, radiotherapy, transarterial chemoembolisation, and percutaneous ethanol injection also show some benefit in the survival of patients with HCC. Future molecular targeted drugs are currently under investigation in different stages of clinical trials, and there are positive expectations regarding their benefit in treating HCC.https://www.emjreviews.com/hepatology/article/hepatocellular-carcinoma-part-3-surgical-and-medical-treatment/Hepatocellular carcinoma (HCC)surgical treatment of HCCmedical treatment of HCC |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lior Charach Lior Zusmanovitch Gideon Charach |
spellingShingle |
Lior Charach Lior Zusmanovitch Gideon Charach Hepatocellular Carcinoma. Part 3: Surgical and Medical Treatment European Medical Journal Hepatology Hepatocellular carcinoma (HCC) surgical treatment of HCC medical treatment of HCC |
author_facet |
Lior Charach Lior Zusmanovitch Gideon Charach |
author_sort |
Lior Charach |
title |
Hepatocellular Carcinoma. Part 3: Surgical and Medical Treatment |
title_short |
Hepatocellular Carcinoma. Part 3: Surgical and Medical Treatment |
title_full |
Hepatocellular Carcinoma. Part 3: Surgical and Medical Treatment |
title_fullStr |
Hepatocellular Carcinoma. Part 3: Surgical and Medical Treatment |
title_full_unstemmed |
Hepatocellular Carcinoma. Part 3: Surgical and Medical Treatment |
title_sort |
hepatocellular carcinoma. part 3: surgical and medical treatment |
publisher |
European Medical Journal |
series |
European Medical Journal Hepatology |
issn |
2053-4221 |
publishDate |
2018-06-01 |
description |
Hepatocellular carcinoma (HCC) treatment is variable and depends on the size, location, and presence of extra hepatic metastasis and vascular invasion. HCC treatment options have advanced significantly over the past few decades and include surgical and non-surgical methods. In the past, systemic chemotherapy was the non-surgical treatment and there was no significant increase in overall survival rate. Nowadays sorafenib, a molecular targeted drug, is the treatment of choice and has shown proven benefits in increasing survival time; other systemic therapies did not show longer statistical superiority. However, surgical treatments, such as liver transplantation and surgical resection, are still the only methods offering a curative opportunity; however, these are not free of adverse effects and recurrence of the tumour. Non-surgical techniques including ablative treatment, radiotherapy, transarterial chemoembolisation, and percutaneous ethanol injection also show some benefit in the survival of patients with HCC. Future molecular targeted drugs are currently under investigation in different stages of clinical trials, and there are positive expectations regarding their benefit in treating HCC. |
topic |
Hepatocellular carcinoma (HCC) surgical treatment of HCC medical treatment of HCC |
url |
https://www.emjreviews.com/hepatology/article/hepatocellular-carcinoma-part-3-surgical-and-medical-treatment/ |
work_keys_str_mv |
AT liorcharach hepatocellularcarcinomapart3surgicalandmedicaltreatment AT liorzusmanovitch hepatocellularcarcinomapart3surgicalandmedicaltreatment AT gideoncharach hepatocellularcarcinomapart3surgicalandmedicaltreatment |
_version_ |
1725574396222898176 |